China's Ascentage Pharma targets $1.8b valuation in US IPO

China's Ascentage Pharma targets $1.8b valuation in US IPO

Photo by Madison Agardi on Unsplash.

Arasu Kannagi Basil, Jaiveer Singh Shekhawat

22 January, 2025

Ascentage Pharma Takeda

Printed by Unregistered user on Thu, 28 Aug 2025 15:03:51 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Takeda to sell Japanese consumer health unit to Blackstone for $2.3b

Indonesia PE-VC Summit 2025

Indonesia’s IPO market likely to get bigger and better this year

Read more from Greater China

Logistics firm GLP secures up to $1.5b from ADIA unit

Earnings and Results

Data Vantage: Foundation Healthcare clocks profit; other financial updates